ArticleBlood cancer journal2021

High-throughput drug screening identifies the ATR-CHK1 pathway as a therapeutic vulnerability of CALR mutated hematopoietic cells.

Ruochen Jia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.